share_log

Earnings Call Summary | CANSORTIUM INC(CNTMF.US) Q4 2023 Earnings Conference

Earnings Call Summary | CANSORTIUM INC(CNTMF.US) Q4 2023 Earnings Conference

業績電話會議摘要 | CANSORTIUM INC (CNTMF.US) 2023 年第四季度業績發佈會
富途資訊 ·  04/30 09:46  · 電話會議

The following is a summary of the Cansortium Inc. (CNTMF) Q4 2023 Earnings Call Transcript:

以下是Cansortium Inc.(CNTMF)2023年第四季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Cansortium reported a Q4 increase in revenue by 9% to $25.5 million, mainly due to new dispensaries in Florida and higher patient counts.

  • The adjusted gross profit for the quarter was 49.4% of revenue, reaching $12.6 million.

  • Positive cash flow from operations was reported for the ninth consecutive quarter, amounting to $1.4 million in Q4.

  • The increased customer transactions throughout 2023 resulted in Adjusted EBITDA of $27.2 million, compared to $25 million in the previous year.

  • Cansortium報告稱,第四季度收入增長了9%,達到2550萬美元,這主要是由於佛羅里達州的新藥房和患者人數的增加。

  • 本季度調整後的毛利爲收入的49.4%,達到1,260萬美元。

  • 連續第九個季度報告了正的運營現金流,第四季度爲140萬美元。

  • 2023年全年客戶交易量的增加使調整後的息稅折舊攤銷前利潤爲2720萬美元,而去年同期爲2500萬美元。

Business Progress:

業務進展:

  • Cansortium opened four new dispensaries in Florida during 2023, anticipating potential expansion into the adult-use market.

  • The company witnessed substantial growth in the Texas market, credited to increases in retail volume and patient growth, predominantly in the Houston area.

  • Cansortium initiated strategic partnerships with wholesale suppliers in Pennsylvania, making them competitively priced in the market.

  • Development plans include opening an education center in Houston by 2025 and the expected operational contribution from the 'Rosa' facility in Q4 2024.

  • 2023年,Cansortium在佛羅里達州開設了四家新藥房,預計有可能向成人用途市場擴張。

  • 該公司見證了德克薩斯州市場的大幅增長,這要歸功於零售量的增加和患者增長,主要集中在休斯敦地區。

  • Cansortium與賓夕法尼亞州的批發供應商建立了戰略合作伙伴關係,使其在市場上具有競爭力的價格。

  • 發展計劃包括到2025年在休斯敦開設教育中心,以及 “羅莎” 設施預計在2024年第四季度提供的運營捐款。

More details: CANSORTIUM INC IR

更多詳情: CANSORTIUM INC IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論